On the public citation graph
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
0 signed · 553 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinte.162.15.1729openalex-snapshot
Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer
inferredcites →https://doi.org/10.1001/jama.2008.656openalex-snapshot
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
inferredcites →https://doi.org/10.1002/14651858.cd006652openalex-snapshot
Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation
inferredcites →https://doi.org/10.1002/bjs.1800730316openalex-snapshot
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
inferredcites →https://doi.org/10.1002/bjs.1800750213openalex-snapshot
Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
inferredcites →https://doi.org/10.1002/bjs.1800750920openalex-snapshot
Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
inferredcites →https://doi.org/10.1002/bjs.1800751105openalex-snapshot
Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
inferredcites →https://doi.org/10.1002/bjs.1800780410openalex-snapshot
Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin
inferredcites →https://doi.org/10.1002/bjs.1800820421openalex-snapshot
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients
inferredcites →https://doi.org/10.1002/bjs.1800840817openalex-snapshot
Efficacy and safety of enoxaparinversus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
inferredcites →https://doi.org/10.1002/bjs.5154openalex-snapshot
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery
inferredcites →https://doi.org/10.1002/cncr.22892openalex-snapshot
A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment
inferredcites →https://doi.org/10.1016/0140-6736(93)92614-yopenalex-snapshot
Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
inferredcites →https://doi.org/10.1016/j.amjmed.2006.02.022openalex-snapshot
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer
inferredcites →https://doi.org/10.1016/j.ejca.2008.09.005openalex-snapshot
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findings
inferredcites →https://doi.org/10.1016/s0140-6736(08)60202-0openalex-snapshot
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
inferredcites →https://doi.org/10.1016/s0140-6736(94)90008-6openalex-snapshot
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
inferredcites →https://doi.org/10.1016/s1359-6349(09)71225-xopenalex-snapshot
6503 Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)
inferredcites →https://doi.org/10.1016/s1470-2045(09)70232-3openalex-snapshot
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
inferredcites →https://doi.org/10.1046/j.1365-2168.1997.d01-3882.xopenalex-snapshot
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
inferredcites →https://doi.org/10.1046/j.1445-5994.2002.00171.xopenalex-snapshot
Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis
inferredcites →https://doi.org/10.1055/s-0038-1650254openalex-snapshot
Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)
inferredcites →https://doi.org/10.1055/s-2007-994925openalex-snapshot
Prevention of Venous Thromboembolism in Cancer Patients
inferredcites →https://doi.org/10.1056/nejm199210153271604openalex-snapshot
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
inferredcites →https://doi.org/10.1056/nejm199802123380701openalex-snapshot
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
inferredcites →https://doi.org/10.1056/nejm199909093411103openalex-snapshot
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
inferredcites →https://doi.org/10.1056/nejm200012213432504openalex-snapshot
Prognosis of Cancers Associated with Venous Thromboembolism
inferredcites →https://doi.org/10.1056/nejmoa012385openalex-snapshot
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
inferredcites →https://doi.org/10.1056/nejmoa025313openalex-snapshot
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
inferredcites →https://doi.org/10.1093/annonc/mdi165openalex-snapshot
Deep vein thrombosis in cancer: the scale of the problem and approaches to management
inferredcites →https://doi.org/10.1093/annonc/mdj059openalex-snapshot
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
inferredcites →https://doi.org/10.1093/annonc/mdm284openalex-snapshot
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
inferredcites →https://doi.org/10.1097/00000658-198808000-00016openalex-snapshot
Prevention of Venous Thromboembolism in General Surgical Patients
inferredcites →https://doi.org/10.1097/00005792-199909000-00001openalex-snapshot
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
inferredcites →https://doi.org/10.1097/00132586-199310000-00032openalex-snapshot
Low Molecular Weight Versus Standard Heparin for Prevention of Venous Thromboembolism After Major Abdominal Surgery
inferredcites →https://doi.org/10.1111/j.1538-7836.2004.00720.xopenalex-snapshot
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial
inferredcites →https://doi.org/10.1111/j.1538-7836.2006.02153.xopenalex-snapshot
Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open‐label study
inferredcites →https://doi.org/10.1111/j.1538-7836.2009.03326.xopenalex-snapshot
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
inferredcites →https://doi.org/10.1136/bmj.38733.466748.7copenalex-snapshot
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
inferredcites →https://doi.org/10.1161/01.cir.0000138928.83266.24openalex-snapshot
Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
inferredcites →https://doi.org/10.1182/blood-2002-01-0108openalex-snapshot
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
inferredcites →https://doi.org/10.1182/blood-2002-01-0335openalex-snapshot
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
inferredcites →https://doi.org/10.1182/blood-2006-01-0154openalex-snapshot
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
inferredcites →https://doi.org/10.1182/blood-2007-10-116327openalex-snapshot
Development and validation of a predictive model for chemotherapy-associated thrombosis
inferredcites →https://doi.org/10.1200/jco.2004.10.002openalex-snapshot
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
inferredcites →https://doi.org/10.1200/jco.2005.03.134openalex-snapshot
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
inferredcites →https://doi.org/10.1200/jco.2005.03.8877openalex-snapshot
Thromboembolism in Hospitalized Neutropenic Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2005.06.084openalex-snapshot
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2005.10.192openalex-snapshot
Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer
inferredcites →https://doi.org/10.1200/jco.2007.14.1283openalex-snapshot
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.4033openalex-snapshot
A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.
inferredcites →https://doi.org/10.1200/jco.2010.31.6844openalex-snapshot
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
inferredcites →https://doi.org/10.4065/81.6.758openalex-snapshot
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
inferredcites →https://doi.org/10.7326/0003-4819-76-3-112-6-423openalex-snapshot
Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4200370openalex-extracted
Development and Validation of a New Risk Assessment Model for Immunomodulatory Drug-Associated Venous Thrombosis Among Chinese Patients with Multiple Myeloma
inferred← citeshttps://doi.org/10.1001/jama.2015.9243openalex-snapshot
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.36304openalex-snapshot
Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.0010openalex-snapshot
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
inferred← citeshttps://doi.org/10.1002/14651858.cd013399openalex-snapshot
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1002/14651858.cd013399.pub2openalex-snapshot
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1002/9781119518495.ch5openalex-snapshot
Preoperative Optimization Prior to Exenteration
inferred← citeshttps://doi.org/10.1002/ajh.26945openalex-snapshot
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial
inferred← citeshttps://doi.org/10.1002/bjs.8990openalex-snapshot
Contemporary perioperative care strategies
inferred← citeshttps://doi.org/10.1002/cam4.1540openalex-snapshot
Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice
inferred← citeshttps://doi.org/10.1002/cam4.3670openalex-snapshot
Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study
inferred← citeshttps://doi.org/10.1002/cam4.4559openalex-snapshot
Venous thromboembolism and radiation therapy: The final radiation‐induced thrombosis study analysis
inferred← citeshttps://doi.org/10.1002/hcs2.55openalex-snapshot
Predicting venous thromboembolism (VTE) risk in cancer patients using machine learning
inferred← citeshttps://doi.org/10.1002/hem3.70163openalex-snapshot
Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro‐HL multicenter study
inferred← citeshttps://doi.org/10.1002/jso.24361openalex-snapshot
Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?
inferred← citeshttps://doi.org/10.1002/jso.24746openalex-snapshot
Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
inferred← citeshttps://doi.org/10.1002/jso.25151openalex-snapshot
Prospective implementation of a standardized screening protocol for deep venous thrombosis in abdominal surgical oncology patients
inferred← citeshttps://doi.org/10.1002/jso.26876openalex-snapshot
Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study
inferred← citeshttps://doi.org/10.1002/pds.5795openalex-snapshot
Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer
inferred← citeshttps://doi.org/10.1002/rth2.12327openalex-snapshot
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
inferred← citeshttps://doi.org/10.1002/rth2.12653openalex-snapshot
Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
inferred← citeshttps://doi.org/10.1002/rth2.12744openalex-snapshot
Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021
inferred← citeshttps://doi.org/10.1007/5584_2016_112openalex-snapshot
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-1-4614-9560-4_11openalex-snapshot
The Excessively Clotting Cancer Patient
inferred← citeshttps://doi.org/10.1007/978-3-030-16245-0_5openalex-snapshot
Genetic Basis of Metastasis
inferred← citeshttps://doi.org/10.1007/978-3-030-23417-1_11openalex-snapshot
Anticoagulation in Patients with Brain Metastases
inferred← citeshttps://doi.org/10.1007/978-3-030-74462-5_10openalex-snapshot
Direct Oral Anticoagulation in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-97687-3_5openalex-snapshot
Gynecological Cancer and Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-17273-1_10openalex-snapshot
Oncologic Emergencies in Patients Undergoing Major Surgery
inferred← citeshttps://doi.org/10.1007/978-3-031-90326-7_2openalex-snapshot
Indications and Contraindications
inferred← citeshttps://doi.org/10.1007/978-3-319-21148-0_10openalex-snapshot
Thromboprophylaxis in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-21683-6_5openalex-snapshot
Genetic Basis of Metastasis
inferred← citeshttps://doi.org/10.1007/978-3-319-43096-6_9openalex-snapshot
Vascular Complications of Cancer and Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-57901-6_23openalex-snapshot
Neurological Complications of Breast Cancer and Its Treatment
inferred← citeshttps://doi.org/10.1007/978-3-319-90990-5_20openalex-snapshot
Anaemia in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-93402-0_5openalex-snapshot
Cardiovascular Damage Induced by Anti-VEGF Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-93572-0_12openalex-snapshot
Hematologic Challenges in ICU Patients with Malignancy
inferred← citeshttps://doi.org/10.1007/978-3-642-54676-1_348-1openalex-snapshot
Venöse Thromboembolie (VTE): Epidemiologie, Pathophysiologie und natürlicher Verlauf
inferred← citeshttps://doi.org/10.1007/978-981-10-7464-6_25openalex-snapshot
Postoperative Management in Patients Undergoing Major Pancreatic Resections
inferred← citeshttps://doi.org/10.1007/s00228-022-03365-4openalex-snapshot
Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses
inferred← citeshttps://doi.org/10.1007/s00345-018-2598-7openalex-snapshot
Predictors of thrombosis in testicular cancer during platinum-based chemotherapy
inferred← citeshttps://doi.org/10.1007/s00384-019-03244-yopenalex-snapshot
The prevalence of venous thromboembolism in rectal surgery: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00432-019-02922-2openalex-snapshot
Neutrophil extracellular traps enhance procoagulant activity in patients with oral squamous cell carcinoma
inferred← citeshttps://doi.org/10.1007/s00464-017-5951-9openalex-snapshot
Perioperative bleeding and blood transfusion are major risk factors for venous thromboembolism following bariatric surgery
inferred← citeshttps://doi.org/10.1007/s00508-018-1381-5openalex-snapshot
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
inferred← citeshttps://doi.org/10.1007/s00520-013-1742-6openalex-snapshot
Thromboembolic disease in cancer patients
inferred← citeshttps://doi.org/10.1007/s00520-014-2170-yopenalex-snapshot
Thromboprophylaxis for lung cancer patients—multimodality assessment of clinician practices, perceptions and decision support tools
inferred← citeshttps://doi.org/10.1007/s00520-017-3610-2openalex-snapshot
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria
inferred← citeshttps://doi.org/10.1007/s00520-017-3990-3openalex-snapshot
The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines
inferred← citeshttps://doi.org/10.1007/s00520-017-4034-8openalex-snapshot
Physicians’ decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France
inferred← citeshttps://doi.org/10.1007/s00520-018-4537-yopenalex-snapshot
Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study
inferred← citeshttps://doi.org/10.1007/s00520-020-05669-6openalex-snapshot
Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist’s impact on anticoagulant therapy
inferred← citeshttps://doi.org/10.1007/s00520-022-07137-9openalex-snapshot
Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)
inferred← citeshttps://doi.org/10.1007/s10120-019-00930-2openalex-snapshot
Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients
inferred← citeshttps://doi.org/10.1007/s10147-018-1290-7openalex-snapshot
Effect of post-filter anticoagulation on mortality in patients with cancer-associated pulmonary embolism
inferred← citeshttps://doi.org/10.1007/s10555-014-9500-xopenalex-snapshot
Clinical models and biochemical predictors of VTE in lung cancer
inferred← citeshttps://doi.org/10.1007/s10585-018-9875-0openalex-snapshot
The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis
inferred← citeshttps://doi.org/10.1007/s11060-016-2106-0openalex-snapshot
Predictors of survival for patients with cancer after cryptogenic stroke
inferred← citeshttps://doi.org/10.1007/s11239-013-1014-9openalex-snapshot
Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s11239-015-1261-zopenalex-snapshot
Heparin: 100 years of pleiotropic effects
inferred← citeshttps://doi.org/10.1007/s11239-015-1313-4openalex-snapshot
Guidance for the prevention and treatment of cancer-associated venous thromboembolism
inferred← citeshttps://doi.org/10.1007/s11239-016-1386-8openalex-snapshot
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
inferred← citeshttps://doi.org/10.1007/s11239-018-1621-6openalex-snapshot
Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center
inferred← citeshttps://doi.org/10.1007/s11239-018-1783-2openalex-snapshot
Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update
inferred← citeshttps://doi.org/10.1007/s11239-019-01809-wopenalex-snapshot
Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis
inferred← citeshttps://doi.org/10.1007/s11239-019-01884-zopenalex-snapshot
Concurrent presentation of a hemorrhagic pericardial effusion and venous thromboembolism in malignancy: a systematic review of case studies
inferred← citeshttps://doi.org/10.1007/s11239-019-01935-5openalex-snapshot
Cancer-associated thromboembolism: antithrombotic management of hospitalized patients
inferred← citeshttps://doi.org/10.1007/s11239-020-02128-1openalex-snapshot
Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin
inferred← citeshttps://doi.org/10.1007/s11239-020-02180-xopenalex-snapshot
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE
inferred← citeshttps://doi.org/10.1007/s11239-021-02512-5openalex-snapshot
Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study
inferred← citeshttps://doi.org/10.1007/s11239-024-02984-1openalex-snapshot
Primary thromboprophylaxis in cancer outpatients – real-world evidence
inferred← citeshttps://doi.org/10.1007/s11739-018-1956-1openalex-snapshot
Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer
inferred← citeshttps://doi.org/10.1007/s11748-024-02062-6openalex-snapshot
Hypercoagulable state and effect of low-molecular-weight heparin prophylaxis on coagulation after lung cancer resection: results from thrombo-elastography
inferred← citeshttps://doi.org/10.1007/s11912-019-0767-5openalex-snapshot
Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid
inferred← citeshttps://doi.org/10.1007/s11912-023-01428-yopenalex-snapshot
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/s11936-016-0445-yopenalex-snapshot
Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/s12032-018-1120-9openalex-snapshot
Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients
inferred← citeshttps://doi.org/10.1007/s12032-019-1331-8openalex-snapshot
Venous thromboprophylaxis in urological cancer surgery
inferred← citeshttps://doi.org/10.1007/s12094-014-1165-yopenalex-snapshot
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model
inferred← citeshttps://doi.org/10.1007/s12094-016-1500-6openalex-snapshot
Safety and efficacy of primary thromboprophylaxis in cancer patients
inferred← citeshttps://doi.org/10.1007/s12094-017-1632-3openalex-snapshot
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
inferred← citeshttps://doi.org/10.1007/s12094-017-1682-6openalex-snapshot
Supportive care in pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s12094-017-1692-4openalex-snapshot
Key points to optimizing management and research on cancer-associated thrombosis
inferred← citeshttps://doi.org/10.1007/s12094-019-02258-wopenalex-snapshot
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin
inferred← citeshttps://doi.org/10.1007/s12094-020-02339-1openalex-snapshot
Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status
inferred← citeshttps://doi.org/10.1007/s12094-024-03635-wopenalex-snapshot
Impact of COVID-19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study
inferred← citeshttps://doi.org/10.1007/s12254-013-0098-4openalex-snapshot
Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment
inferred← citeshttps://doi.org/10.1007/s12282-019-00990-3openalex-snapshot
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
inferred← citeshttps://doi.org/10.1007/s12325-015-0271-8openalex-snapshot
Transitions in the Prophylaxis, Treatment and Care of Patients with Venous Thromboembolism
inferred← citeshttps://doi.org/10.1007/s13193-021-01281-0openalex-snapshot
A Prospective Observational Study to Determine Rate of Thromboprophylaxis in Oncology Patients Undergoing Abdominal or Pelvic Surgery
inferred← citeshttps://doi.org/10.1007/s15015-012-0426-2openalex-snapshot
Gerinnungsstörungen und Thrombosen bei onkologischen Patienten
inferred← citeshttps://doi.org/10.1007/s40265-015-0526-3openalex-snapshot
Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy
inferred← citeshttps://doi.org/10.1007/s40265-019-01084-2openalex-snapshot
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/b978-0-12-802997-8.00015-3openalex-snapshot
Vascular complications in glioma patients
inferred← citeshttps://doi.org/10.1016/b978-0-323-44227-5.00011-9openalex-snapshot
Thromboembolic Disease in Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-46202-0.00023-6openalex-snapshot
Thrombosis and Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00033-5openalex-snapshot
Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis
inferred← citeshttps://doi.org/10.1016/b978-1-4557-2865-7.00035-7openalex-snapshot
Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism
inferred← citeshttps://doi.org/10.1016/bs.acc.2021.03.001openalex-snapshot
The prothrombotic state in cancer
inferred← citeshttps://doi.org/10.1016/j.achaem.2015.08.002openalex-snapshot
Concomitant history of cancer in acute pulmonary embolism is connected with poorer outcome
inferred← citeshttps://doi.org/10.1016/j.achaem.2016.06.001openalex-snapshot
Zalecenia dotyczące oceny schorzeń współistniejących u chorych na przewlekłą białaczkę szpikową w procesie wyboru inhibitora kinaz tyrozynowych
inferred← citeshttps://doi.org/10.1016/j.ajog.2018.07.014openalex-snapshot
Surgical technical evidence review for gynecologic surgery conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery
inferred← citeshttps://doi.org/10.1016/j.amjoto.2022.103722openalex-snapshot
Preoperative low-molecular weight heparin chemoprophylaxis in head and neck free flap reconstruction
inferred← citeshttps://doi.org/10.1016/j.amjsurg.2014.12.051openalex-snapshot
Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer
inferred← citeshttps://doi.org/10.1016/j.amjsurg.2017.08.032openalex-snapshot
Venous thromboembolism in common laparoscopic abdominal surgical operations
inferred← citeshttps://doi.org/10.1016/j.amjsurg.2018.11.046openalex-snapshot
Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery
inferred← citeshttps://doi.org/10.1016/j.annemergmed.2016.12.003openalex-snapshot
Management of Cancer-Associated Venous Thromboembolism in the Emergency Department
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.11.003openalex-snapshot
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.anplas.2017.11.001openalex-snapshot
Venous thromboembolism events after breast reconstructions with DIEP free flaps in 192 consecutive case
inferred← citeshttps://doi.org/10.1016/j.arcped.2017.10.029openalex-snapshot
La maladie thrombo-embolique veineuse en oncologie pédiatrique
inferred← citeshttps://doi.org/10.1016/j.asjsur.2018.12.013openalex-snapshot
Venous thromboembolism in colorectal surgery: Incidence, risk factors, and prophylaxis
inferred← citeshttps://doi.org/10.1016/j.bbcan.2022.188778openalex-snapshot
Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence
inferred← citeshttps://doi.org/10.1016/j.bcp.2015.07.013openalex-snapshot
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells
inferred← citeshttps://doi.org/10.1016/j.beha.2013.07.004openalex-snapshot
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
inferred← citeshttps://doi.org/10.1016/j.beha.2022.101351openalex-snapshot
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting
inferred← citeshttps://doi.org/10.1016/j.blre.2013.11.001openalex-snapshot
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
inferred← citeshttps://doi.org/10.1016/j.blre.2017.10.002openalex-snapshot
Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment
inferred← citeshttps://doi.org/10.1016/j.bpa.2013.09.001openalex-snapshot
Haemostatic challenges in the cancer patient: Focus on the perioperative period
inferred← citeshttps://doi.org/10.1016/j.bulcan.2017.12.006openalex-snapshot
Cancer et récidive thromboembolique veineuse : les clés d’une prise en charge optimale
inferred← citeshttps://doi.org/10.1016/j.chest.2015.10.069openalex-snapshot
Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer
inferred← citeshttps://doi.org/10.1016/j.chest.2020.08.002openalex-snapshot
Inferior Vena Cava Filters
inferred← citeshttps://doi.org/10.1016/j.chest.2026.05.035openalex-snapshot
Recurrent VTE During Anticoagulation
inferred← citeshttps://doi.org/10.1016/j.clgc.2022.10.005openalex-snapshot
Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy
inferred← citeshttps://doi.org/10.1016/j.clml.2017.02.006openalex-snapshot
Thoracic Complications in Chronic Lymphocytic Leukemia
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.06.015openalex-snapshot
Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.07.005openalex-snapshot
Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.09.015openalex-snapshot
Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug–drug interactions
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103125openalex-snapshot
Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102280openalex-snapshot
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.disamonth.2016.03.003openalex-snapshot
Cancer-associated thrombosis
inferred← citeshttps://doi.org/10.1016/j.ejim.2019.10.033openalex-snapshot
Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100225openalex-snapshot
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines
inferred← citeshttps://doi.org/10.1016/j.heliyon.2016.e00229openalex-snapshot
Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism
inferred← citeshttps://doi.org/10.1016/j.ijscr.2022.106836openalex-snapshot
Asymptomatic pulmonary thromboembolism diagnosed based on prolonged fever after gastric cancer surgery
inferred← citeshttps://doi.org/10.1016/j.ijsu.2021.105946openalex-snapshot
Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.ijsu.2021.106032openalex-snapshot
A commentary on “Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study” (Int J Surg 2021; 89:105946)
inferred← citeshttps://doi.org/10.1016/j.jaccao.2019.11.007openalex-snapshot
Proceedings From the Global Cardio-Oncology Summit
inferred← citeshttps://doi.org/10.1016/j.jaccao.2021.03.001openalex-snapshot
Venous and Arterial Thromboembolism in Patients With Cancer
inferred← citeshttps://doi.org/10.1016/j.jamcollsurg.2015.11.011openalex-snapshot
Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism
inferred← citeshttps://doi.org/10.1016/j.jamcollsurg.2017.06.017openalex-snapshot
Surgical Technical Evidence Review for Colorectal Surgery Conducted for the AHRQ Safety Program for Improving Surgical Care and Recovery
inferred← citeshttps://doi.org/10.1016/j.jdmv.2017.07.002openalex-snapshot
Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists
inferred← citeshttps://doi.org/10.1016/j.jdmv.2017.09.006openalex-snapshot
Nouvelles recommandations internationales pour le traitement curatif et prophylactique de la maladie thromboembolique veineuse chez les patients atteints d’un cancer et application dédiée pour smartphone
inferred← citeshttps://doi.org/10.1016/j.jdmv.2021.08.001openalex-snapshot
Patient education program at the forefront of cancer-associated thrombosis care
inferred← citeshttps://doi.org/10.1016/j.jemermed.2019.08.010openalex-snapshot
Oncologic Emergencies: Too Much Clotting—Venous Thromboembolism in Malignancy
inferred← citeshttps://doi.org/10.1016/j.jtha.2023.07.007openalex-snapshot
Neutrophil extracellular trap formation is an independent risk factor for occult cancer in patients presenting with venous thromboembolism
inferred← citeshttps://doi.org/10.1016/j.juro.2017.08.130openalex-snapshot
Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines
inferred← citeshttps://doi.org/10.1016/j.kint.2026.09.007openalex-snapshot
Recommendations for the Management of Anemia in Patients with Cancer and Chronic Kidney Disease: A Position Statement from the American Society of Onco-Nephrology (ASON)
inferred← citeshttps://doi.org/10.1016/j.lpm.2016.07.026openalex-snapshot
After deep vein thrombosis, which patients refer to vascular specialist for anticoagulant withdrawal? A Delphi study results between general practitioners and vascular specialists
inferred← citeshttps://doi.org/10.1016/j.lungcan.2014.02.009openalex-snapshot
Thromboembolism in lung cancer – An area of urgent unmet need
inferred← citeshttps://doi.org/10.1016/j.medcle.2019.01.023openalex-snapshot
Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
inferred← citeshttps://doi.org/10.1016/j.medcli.2019.01.002openalex-snapshot
Los anticoagulantes orales de acción directa en el tratamiento de la enfermedad tromboembólica venosa asociada a cáncer
inferred← citeshttps://doi.org/10.1016/j.medpal.2013.08.004openalex-snapshot
Thrombosis prevention in adults in an oncology palliative care setting: Formal expert consensus
inferred← citeshttps://doi.org/10.1016/j.pharep.2016.07.003openalex-snapshot
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1016/j.phrs.2017.03.026openalex-snapshot
Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective
inferred← citeshttps://doi.org/10.1016/j.rec.2014.12.002openalex-snapshot
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
inferred← citeshttps://doi.org/10.1016/j.resinv.2020.11.007openalex-snapshot
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
inferred← citeshttps://doi.org/10.1016/j.rvm.2013.10.005openalex-snapshot
Management of venous thromboembolism in cancer patients
inferred← citeshttps://doi.org/10.1016/j.surg.2018.05.028openalex-snapshot
Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1016/j.thromres.2012.11.014openalex-snapshot
A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin
inferred← citeshttps://doi.org/10.1016/j.thromres.2013.10.027openalex-snapshot
High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: A single center retrospective study
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.01.010openalex-snapshot
Life-Threatening Complications and Outcomes in Patients with Malignancies and Severe Pulmonary Embolism
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.07.011openalex-snapshot
Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.08.002openalex-snapshot
Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis
inferred← citeshttps://doi.org/10.1016/j.thromres.2015.08.010openalex-snapshot
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
inferred← citeshttps://doi.org/10.1016/j.thromres.2016.10.007openalex-snapshot
Comparison of postoperative venous thromboembolism incidence in gastrointestinal and gynecologic solid tumors
inferred← citeshttps://doi.org/10.1016/j.thromres.2016.10.020openalex-snapshot
A systematic review of biomarkers for the prediction of thromboembolism in lung cancer — Results, practical issues and proposed strategies for future risk prediction models
inferred← citeshttps://doi.org/10.1016/j.thromres.2016.12.017openalex-snapshot
Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis
inferred← citeshttps://doi.org/10.1016/j.thromres.2018.01.031openalex-snapshot
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?
inferred← citeshttps://doi.org/10.1016/j.thromres.2019.02.031openalex-snapshot
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants
inferred← citeshttps://doi.org/10.1016/j.thromres.2019.06.005openalex-snapshot
Neutrophil extracellular traps induced by activated platelets contribute to procoagulant activity in patients with colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.thromres.2020.02.005openalex-snapshot
Patient characteristics and long–term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.04.009openalex-snapshot
Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer
inferred← citeshttps://doi.org/10.1016/j.thromres.2025.109287openalex-snapshot
Venous thromboembolism in children with Hodgkin lymphoma – A population-based study in Sweden, Finland, and Denmark
inferred← citeshttps://doi.org/10.1016/j.transci.2012.06.010openalex-snapshot
Thrombotic risk in patients undergoing peripheral stem cell apheresis and low-molecular weight heparin prophylaxis pre-apheresis
inferred← citeshttps://doi.org/10.1016/j.ygyno.2024.12.015openalex-snapshot
Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy
inferred← citeshttps://doi.org/10.1016/s0049-3848(12)70027-0openalex-snapshot
New and old anticoagulants in cancer
inferred← citeshttps://doi.org/10.1016/s0049-3848(12)70034-8openalex-snapshot
Thromboprophylaxis in non-surgical cancer patients
inferred← citeshttps://doi.org/10.1016/s0049-3848(12)70035-xopenalex-snapshot
Treatment of established thrombotic events in patients with cancer
inferred← citeshttps://doi.org/10.1016/s0049-3848(14)50006-0openalex-snapshot
Risk stratification strategies for cancer-associated thrombosis: an update
inferred← citeshttps://doi.org/10.1016/s0049-3848(14)50021-7openalex-snapshot
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer
inferred← citeshttps://doi.org/10.1016/s0049-3848(14)50022-9openalex-snapshot
New strategies of VTE prevention in cancer patients
inferred← citeshttps://doi.org/10.1016/s0049-3848(14)50027-8openalex-snapshot
Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants
inferred← citeshttps://doi.org/10.1016/s0049-3848(15)50434-9openalex-snapshot
Guidelines for the management of cancer and thrombosis – Special aspects in women
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30104-9openalex-snapshot
Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30108-6openalex-snapshot
Primary prophylaxis of VTE in cancer outpatients
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30110-4openalex-snapshot
Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology
inferred← citeshttps://doi.org/10.1016/s0049-3848(16)30111-6openalex-snapshot
Management of recurrent venous thromboembolism in cancer patients
inferred← citeshttps://doi.org/10.1016/s0049-3848(20)30397-2openalex-snapshot
Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer
inferred← citeshttps://doi.org/10.1016/s0049-3848(20)30409-6openalex-snapshot
Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life
inferred← citeshttps://doi.org/10.1016/s0246-0378(17)56534-3openalex-snapshot
10.1016/s0246-0378(17)56534-3
inferred← citeshttps://doi.org/10.1016/s2352-3026(14)70020-1openalex-snapshot
Treating clots in cancer: moving closer to an answer?
inferred← citeshttps://doi.org/10.1016/s2352-3026(16)30057-6openalex-snapshot
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
inferred← citeshttps://doi.org/10.1024/0301-1526/a000684openalex-snapshot
Management of cancer-associated venous thromboembolism – a case-based practical approach
inferred← citeshttps://doi.org/10.1024/1661-8157/a002881openalex-snapshot
Direkte orale Antikoagulanzien bei Krebspatienten: Sind wir so weit?
inferred← citeshttps://doi.org/10.1038/s41416-018-0027-8openalex-snapshot
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
inferred← citeshttps://doi.org/10.1038/s41598-020-58345-4openalex-snapshot
Prognosis and risk factors in older patients with lung cancer and pulmonary embolism: a propensity score matching analysis
showing the first 200 of 499 · page through all 499
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.